Niagen Bioscience (NAGE) Osake Kurssi

Chromadex Corp is primarily active in the industries of nutraceuticals, pharmaceuticals, and food and beverage.

The main competitors of Chromadex Corp in the market include companies like Amarin Corporation, ProPhase Labs, and Natural Alternatives International.

Chromadex Corp is a leading health and wellness company specializing in the discovery, development, and commercialization of innovative ingredients. Established in 1999, Chromadex Corp has grown to become a trusted name in the field, supplying cutting-edge solutions to the dietary supplement, food, beverage, and pharmaceutical industries. With a mission to transform scientific discoveries into life-changing products, Chromadex Corp has a track record of pioneering research and strategic collaborations. As a publicly traded company listed under the symbol CDXC, Chromadex Corp continues to expand its portfolio of patented ingredients and remains committed to delivering high-quality, evidence-based solutions for health-conscious consumers worldwide.

Chromadex Corp, a leading provider of science-based solutions, has achieved several significant milestones. The company successfully developed and commercialized NR (nicotinamide riboside), a breakthrough ingredient in the health industry. Chromadex Corp also established strategic partnerships with major companies like Nestle Health Science and Thorne Research. Additionally, the company has expanded its product portfolio with innovative formulations, including Tru Niagen® – the first and only commercially available form of NR for use in dietary supplements. Chromadex Corp's commitment to scientific research, extensive collaborations, and continuous product innovation have contributed to its impressive growth and recognition in the health and wellness sector.

Chromadex Corp primarily operates in the United States, with headquarters in Irvine, California. The company's presence extends globally, with a focus on various regions including North America, Europe, and Asia. Chromadex Corp is committed to expanding its international footprint and establishing strategic partnerships worldwide to further enhance its market position.

Chromadex Corp represents values of innovation, integrity, and excellence. With a focus on advancing scientific research, Chromadex strives to provide high-quality ingredients and products for the wellness, pharmaceutical, and dietary supplement industries. The company's corporate philosophy revolves around fostering partnerships, conducting rigorous testing, and adhering to industry regulations and ethical standards. By continuously developing and commercializing novel technologies and natural product discoveries, Chromadex aims to contribute to the well-being of individuals and improve the world we live in. With its commitment to quality and forward-thinking approaches, Chromadex Corp stands as a leading player in the industry.

12 analyytikkoa arvioi tällä hetkellä Niagen Bioscience-osaketta: 11 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Niagen Bioscience-yhtiöltä 131,69 M USD liikevaihtoa ja 0,12 USD osakekohtaista tulosta.

Niagen Bioscience Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Niagen Bioscience-osake noteerataan hintaan 2,23 EUR (2,51 USD).

Niagen Bioscience-osake (NAGE) on listattuna 4 pörssissä, muun muassa: NASDAQ (CDXC), Frankfurt (OCD1.F), München (OCD1.MU), Düsseldorf (OCD1.DU).

Chromadex Corp is a scientifically oriented company that specializes in the development and marketing of dietary supplements. The company is a global leader in the research, development, and manufacturing of innovative and natural products using advanced technologies. The company operates in three divisions: Nutraceuticals, Ingredients, and Analytical Testing. Each division offers unique products and services, allowing Chromadex to target a wide range of customers. The Nutraceutical division focuses on the development, production, and marketing of dietary supplements. The product range includes various complementary products that are of interest to customers seeking a healthy lifestyle. Tru Niagen, an advanced dietary supplement based on natural ingredients with anti-aging and energy-boosting effects, is among these products. Tru Niagen is the result of years of research and is one of the most innovative products on the market. The second division, Ingredients, focuses on supplying high-quality ingredients to customers in the food, beverage, and cosmetics industries. Through the use of advanced technology and collaboration with the company's leading scientists, Chromadex develops high-quality products that help customers expand their product range. Natural ingredients such as plant extracts and complexes are particularly sought after. The Analytical Testing division provides independent and precise analysis of food, dietary supplements, and pharmaceuticals. Chromadex utilizes advanced technology and experienced staff to ensure the quality and safety of products before they are brought to market. Chromadex is a pioneer in the application of chromatography technology to accurately identify and quantify phytonutrients and other important compounds in food and dietary supplements. This method allows for a thorough exploration of potential active ingredients and nutrients, enhancing their effectiveness and function in the food industry or as dietary supplements. Chromadex has always been committed to working based on scientific methodology and best practices in the industry. The company collaborates closely with a variety of researchers and scientists, creating innovations that provide clear benefits to customers. Due to these values, Chromadex is able to remain innovative and competitive in the industry and solidify its position as a market leader in the global dietary supplement market.

odotettu liikevaihto Niagen Bioscience on 131,69 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Niagen Bioscience on 10,31 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Niagen Bioscience:n hinta-voitto-suhde (P/E) on tällä hetkellä 20,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Niagen Bioscience-osakkeen arvostusta.

Niagen Bioscience:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,61. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Niagen Bioscience-osakkeen arvostuskennuslukuna.

Niagen Bioscience:n Eulpool-laatuscore on 7/10.

Niagen Bioscience:n ISIN on US1710774076. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Niagen Bioscience:n WKN on A2AG5N. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Niagen Bioscience:n ticker on NAGE. Tämä pörssinoteeraus käytetään Niagen Bioscience-osakkeiden kauppaan pörssissä.